Physician profile
John Daniel
NPI 1427007996
$5,380.38
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $992 · 2021: $1,324 · 2022: $1,241 · 2023: $692 · 2024: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $870.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $783.30 | 2020-2024 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $577.25 | 2019-2023 | Rybelsus, Ozempic |
| Amgen INC. | $481.23 | 2019-2022 | |
| Glaxosmithkline, LLC. | $440.09 | 2019-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $331.81 | 2019-2023 | Farxiga |
| Pfizer INC. | $317.93 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.34 | 2019-2022 | |
| Abbott Laboratories | $238.83 | 2020-2024 | Amplatzer Piccolo, Freestyle Libre 3 |
| Astellas Pharma US INC | $220.07 | 2019-2021 | |
| Lilly USA, LLC | $209.34 | 2019-2023 | Mounjaro, Trulicity |
| Merck Sharp & Dohme LLC | $170.66 | 2019-2023 | Steglatro, Belsomra, Januvia |
| Insightec,INC | $149.64 | 2023-2024 | Exablate |
| Amarin Pharma, INC. | $143.50 | 2019-2021 | |
| Esperion Therapeutics, INC. | $106.64 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $80.97 | 2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.